Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
ADA, adenosine, al, amplify, antioxidant, anytime, argued, ascending, ATP, attack, Bancorp, bardoxolone, blockade, blunting, California, campaign, cap, caption, categorized, CF, CFRD, chamber, characteristic, Cherry, Chuck, Circuit, cobalt, complement, Condensed, constantly, contemporary, CoPP, corridor, cystic, cytokine, defective, dental, dimethyl, DKA, donut, Duane, electrophilic, Elevage, estimand, excursion, exocrine, expedient, faith, fatal, fatty, feedback, fumarate, Grassley, gut, heme, hemin, Hersh, Hill, hole, implicit, incretin, indeterminate, internationally, invading, IX, judge, Kozlov, lessor, likewise, lung, mealtime, microglia, mimetic, mitochondria, mitochondrial, mouse, NASH, NJ, ODD, operationally, Oxidation, oxidative, Oxley, oxygen, pair, persistent, pramlintide, prandial, proinflammatory, protoporphyrin, pulmonary, reactive, redox, relaxing, repayment, repressor, reprogrammed, reprogramming, restraining, Ron, ROS, scarring, Schorr, sickle, signaling, stand, sticky, stimuli, strong, suppressed, suppressing, Tecfidera, Temple, tenant, thick, tool, transcriptional, triphosphate, ubiquity, unresolved, veto, vision, vowed, week, Western, Wolf, Wyden
Removed:
absorbed, added, AEs, AGATA, Altstiel, antidiabetic, arm, Atopic, attain, attendant, BID, blocking, bringing, Byetta, Calithera, Cambrex, canagliflozin, chosen, combat, comparison, complying, concept, confirm, Connecticut, contraindication, contributor, Craig, criterion, deliverable, denying, dependence, Diabetology, differentiation, diminishing, divided, durability, encoding, enzyme, epidemic, equally, exenatide, experimental, expiring, fat, finalized, frequent, gastrointestinal, gene, GKRP, glycemia, hexokinase, Hua, hyperlipidemia, hyperstimulation, identification, improving, infection, injectable, interaction, irrevocably, kg, lab, Larry, lessee, leverage, Lilly, line, lipid, liraglutide, LOGRA, losing, Mendenhall, microvascular, mimic, modulate, monotherapy, muscle, mutation, naturally, numerically, obesity, occurring, optional, Oramed, overcome, paradigm, pathological, Pegbio, PharmaCore, pioglitizone, Pkwy, powered, powerful, preceding, preventative, proven, randomized, reducing, renal, rent, resistance, saxagliptin, secondary, secrete, semaglutide, sense, sensitivity, showed, sitagliptin, stable, Steven, stimulate, suffering, suggested, superiority, supporting, symptom, Teijin, tract, typical, urinary, urine, UTI, validated, Victoza, Wall, Yabao
Filing tables
Filing exhibits
Related press release
VTVT similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
| (1) | Registration Statement (Form S-8 No. 333-206335) pertaining to the vTv Therapeutics Inc. 2015 Omnibus Equity Incentive Plan, and |
| (2) | Registration Statement (Form S-3 No. 333-223269) of vTv Therapeutics Inc., and |
| (3) | Registration Statement (Form S-3 No. 333-232571) of vTv Therapeutics Inc.; |
of our report dated February 20, 2020 with respect to the consolidated financial statements of vTv Therapeutics Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Raleigh, North Carolina
February 20, 2020